Evaxion Biotech AS Cash Flow-to-Debt Ratio
Evaxion Biotech AS cash flow-to-debt ratio. Evaxion Biotech AS (EVAX) has a Cash Flow-to-Debt Ratio of -0.58x as of December 2025, meaning its operating cash flow of $-6.65 Million could theoretically repay -1% of its total liabilities ($11.37 Million) in one year. See Evaxion Biotech AS leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Evaxion Biotech AS (2018–2025)
Cash flow-to-debt ratio of Evaxion Biotech AS from 2018 to 2025. Historical debt coverage capacity for Evaxion Biotech AS across 8 annual periods. Also explore Evaxion Biotech AS (EVAX) net asset momentum to track the company's year-over-year net asset growth rate.
Evaxion Biotech AS Cash Flow-to-Debt Ratio by Year (2018–2025)
Evaxion Biotech AS cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Evaxion Biotech AS. For the full cash flow conversion analysis, see Evaxion Biotech AS cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.58x | $-6.65 Million | $11.37 Million | ▲ +36.1% |
| 2024 | -0.92x | $-12.94 Million | $14.14 Million | ▲ +8.8% |
| 2023 | -1.00x | $-17.69 Million | $17.62 Million | ▲ +46.5% |
| 2022 | -1.88x | $-25.77 Million | $13.72 Million | ▲ +33.8% |
| 2021 | -2.84x | $-21.93 Million | $7.73 Million | ▼ -12.5% |
| 2020 | -2.52x | $-12.44 Million | $4.93 Million | ▲ +38.1% |
| 2019 | -4.08x | $-7.03 Million | $1.72 Million | ▼ -1835.4% |
| 2018 | -0.21x | $-1.99 Million | $9.44 Million | — |